“The Peruvian Institute of Health Technology Assessment and Research (IETSI) has the vision of being a leading organization in the development and assessment of scientific evidence to inform healthcare decision making and advance health resource utilization at a national and regional level.”
– Dr. Patricia Pimentel Álvarez, Director, IETSI
History and Structure
IETSI belongs to the Peruvian Social Security Healthcare System (EsSalud) and was founded in 2014. It is responsible for the development of health technology assessments and scientific research to inform decision-making pertaining novel healthcare technologies. If approved, EsSalud is legally accountable for funding evidence-based healthcare technologies nationwide.
IETSI has three Directorates: The Directorate of Health Technology Assessment, The Directorate of Clinical Practice guidelines, Pharmacovigilance and Technovigilance, and The Directorate of Health Research. IETSI’s house staff consists of a diverse team of skilled and dedicated professionals with different training backgrounds such as medical doctors, nurses, pharmacists, biologists and biomedical engineers.
IETSI aims to improve Peruvian citizens’ healthcare outcomes through the development and assessment of scientific evidence.
How the agency works
IETSI’s Directorate of Health Technology Assessment team receives health technology assessment requests arising from EsSalud healthcare centers nationwide. The team retrieves all the relevant scientific evidence and conducts a comprehensive analysis that leads to the production of health technology assessment reports. All of IETSI’s reports bear evidence-based recommendations and a funding approval or disapproval decision concerning novel healthcare technologies.
IETSI’s HTA reports are disseminated through EsSalud’s official website and are made available to any internet user. Likewise, IETSI’s reports can be found on the Health Technology Assessment Network of the Americas (REDETSA) website (a nonprofit network formed by ministries of health, regulatory authorities, health technology assessment agencies, collaborating centers of the Pan American Health Organization/World Health Organization (PAHO/WHO), and research and education institutions in the Region of the Americas). Other dissemination strategies include participation in national and international academic conferences.
Recently Completed or Milestone Projects
IETSI is the first Peruvian agency to produce and advance the utilization of health technology assessment to guide clinical and public policy decision making. Since its foundation, IETSI has produced more than 240 health technology assessment reports. Some of the recently published HTA reports are:
- Efficacy and safety of daratumumab plus bortezomib and dexamethasone in relapsed or refractory multiple myeloma
- Efficacy and safety of 9-Valent Human Papillomavirus (HPV) Vaccine in 9-26-Year-Old Patients with HIV
- Efficacy and safety of cetuximab in Patients With KRAS/RAS Wild-Type and left-sided Metastatic Colorectal Cancer
- Efficacy and safety of imiglucerase for the treatment of Gaucher Disease type 1
- Efficacy and safety of empagliflozin in adults with type 2 diabetes mellitus and established cardiovascular disease
To advance the field of evidence-based health care policy development through the incorporation of strategies such as network collaboration and patient shared-decision making.
Description of population served: EsSalud isa nationwide healthcare system that cares for 35.7% of the Peruvian population
Size of population served: 11 million
Current HTA budget (mil USD): IETSI’s annual budget for 2019 is approximately 2.6 million USD
# Permanent staff: 50
# Consultants: Variable
# Ongoing TA projects: –
Contact person: Dr. Patricia Pimentel Álvarez, Director, IETSIIETSI
Jr. Domingo Cueto 120, Jesús María
Fax number: –